NDTP — NDT Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $14.48m
- $14.42m
Annual income statement for NDT Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2007 December 31st | 2008 December 31st | C2009 December 31st | 2010 December 31st | 2011 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | ARS | ARS | ARS | ARS |
| Standards: | USG | — | — | — | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.027 | 0.008 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.04 | 0.052 | 1.06 | 0.254 | 0.031 |
| Operating Profit | -1.04 | -0.052 | -1.04 | -0.246 | -0.031 |
| Net Income Before Taxes | -1.04 | -0.052 | -1.04 | -0.246 | -0.031 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.04 | -0.052 | -1.04 | -0.246 | -0.031 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.04 | -0.052 | -1.04 | -0.246 | -0.031 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -1.04 | -0.052 | -1.04 | -0.246 | -0.031 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.851 | -1.51 | -24.4 | -0.709 | -0.032 |
| Dividends per Share |